TD Cowen analyst Tyler Van Buren downgraded Keros Therapeutics (NASDAQ: KROS) from Buy to Hold.The analyst comments "Following the unexpected ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE